Home LiteratureArticle Details
PMID: 16150856 Published · ppublish English Clinical Trial Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C.

Gut ·Vol. 55 ·No. 3 ·2006-03-00 ·Pages 374-9

Diago M, Castellano G, García-Samaniego J, Pérez C, Fernández I, Romero M, Iacono OL, García-Monzón C

Abstract

Increased serum and intrahepatic interferon gamma inducible protein 10 (IP-10) levels in patients with chronic hepatitis C (CHC) have been described. To analyse the possible association of serum IP-10 levels with different outcomes to antiviral therapy. A total of 137 CHC patients treated with peginterferon plus ribavirin. Serum IP-10 levels were determined by enzyme linked immunosorbent assay before therapy, after 12 weeks of treatment, and 24 weeks after cessation of therapy. Variables significantly associated with a sustained virological response (SVR) on univariate analysis were included in a multivariate logistic regression model. Pretreatment serum IP-10 levels in patients with SVR were significantly lower than in non-responders (NR) (332.4 (222.1) v 476.8 (305.3) pg/ml, respectively; p=0.004). Serum IP-10 concentrations significantly decreased in patients with SVR (pretreatment: 332.4 (222.1) pg/ml; post-treatment: 170.2 (140.1) pg/ml; p<0.001) but not in NR (pretreatment: 476.8 (305.3) pg/ml; post treatment: 387.3 (268.1) pg/ml; p=0.06). By multivariate analysis, non-1 genotype (odds ratio (OR) 3.5 (95% confidence interval (CI) 1.1-10.4); p=0.003) and low viral load at baseline (OR 0.34 (95% CI 0.14-0.79); p=0.01) were independent predictors of SVR in all patients. When multivariate analysis was restricted to patients with genotype 1, only baseline viral load (OR 0.38 (95% CI 0.155-0.96); p=0.04) and pretreatment serum IP-10 levels (OR 0.99 (95% CI 0.996-0.999); p=0.03) were identified as predictive factors of SVR. Pretreatment serum IP-10 behaves as a predictive factor of SVR to peginterferon plus ribavirin therapy in genotype 1 infected patients.

MeSH Terms
Adult Aged Antiviral Agents/therapeutic use Biomarkers/blood Chemokine CXCL10 Chemokines, CXC/blood Drug Therapy, Combination Enzyme-Linked Immunosorbent Assay/methods Female Genotype Hepacivirus/genetics Hepatitis C, Chronic/blood,drug therapy,virology Humans Interferon alpha-2 Interferon-alpha/therapeutic use Male Middle Aged Polyethylene Glycols/therapeutic use Prognosis Recombinant Proteins Ribavirin/therapeutic use Treatment Outcome Viral Load
Chemicals
Antiviral Agents Biomarkers Chemokine CXCL10 Chemokines, CXC Interferon alpha-2 Interferon-alpha Recombinant Proteins Polyethylene Glycols Ribavirin peginterferon alfa-2b peginterferon alfa-2a
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Diago M
Section of Hepatology, University General Hospital, Valencia, Spain.
Castellano G
García-Samaniego J
Pérez C
Fernández I
Romero M
Iacono O L
García-Monzón C
References (37)
37 references, click to expand
  1. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver.
    J Immunol. 1999 Dec 1;163(11):6236-43 PMID: 10570316
  2. Histological grading and staging of chronic hepatitis.
    J Hepatol. 1995 Jun;22(6):696-9 PMID: 7560864
  3. Pathogenesis, natural history, treatment, and prevention of hepatitis C.
    Ann Intern Med. 2000 Feb 15;132(4):296-305 PMID: 10681285
  4. Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection.
    Clin Exp Immunol. 2000 Mar;119(3):479-85 PMID: 10691920
  5. Chemokine receptors and their role in inflammation and infectious diseases.
    Blood. 2000 May 15;95(10):3032-43 PMID: 10807766
  6. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C.
    Hepatology. 1996 Feb;23(2):210-7 PMID: 8591843
  7. IL-1 beta and TNF-alpha produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C.
    Dig Dis Sci. 1996 Feb;41(2):315-21 PMID: 8601375
  8. Factors affecting treatment responses to interferon-alpha in chronic hepatitis C.
    J Infect Dis. 1996 Jul;174(1):1-7 PMID: 8655978
  9. Chemokines in viral disease.
    Res Virol. 1996 Mar-Jun;147(2-3):131-8 PMID: 8901432
  10. Human chemokines: an update.
    Annu Rev Immunol. 1997;15:675-705 PMID: 9143704
  11. Natural history of hepatitis C.
    Hepatology. 1997 Sep;26(3 Suppl 1):21S-28S PMID: 9305659
  12. Chemokines--chemotactic cytokines that mediate inflammation.
    N Engl J Med. 1998 Feb 12;338(7):436-45 PMID: 9459648
  13. Gene expression profile of T-cell-specific chemokines in human hepatocyte-derived cells: evidence for a synergistic inducer effect of cytokines and hepatitis C virus proteins.
    J Viral Hepat. 2005 Jan;12(1):27-37 PMID: 15655045
  14. CXCR3, IP-10, and Mig are required for CD4+ T cell recruitment during the DTH response to HSV-1 yet are independent of the mechanism for viral clearance.
    Virology. 2005 Mar 1;333(1):1-9 PMID: 15708587
  15. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.
    Gastroenterology. 2005 Mar;128(3):636-41 PMID: 15765399
  16. Enhanced expression of interferon-regulated genes in the liver of patients with chronic hepatitis C virus infection: detection by suppression-subtractive hybridization.
    J Virol. 2001 Feb;75(3):1332-8 PMID: 11152506
  17. Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes.
    J Biol Chem. 2001 Mar 30;276(13):9945-54 PMID: 11136732
  18. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response.
    J Virol. 2001 Jul;75(13):6095-106 PMID: 11390611
  19. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy.
    J Virol. 2001 Jul;75(13):6209-11 PMID: 11390624
  20. Hepatitis C virus infection.
    N Engl J Med. 2001 Jul 5;345(1):41-52 PMID: 11439948
  21. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
    Lancet. 2001 Sep 22;358(9286):958-65 PMID: 11583749
  22. Cytokine receptors and signaling in hepatic stellate cells.
    Semin Liver Dis. 2001 Aug;21(3):397-416 PMID: 11586468
  23. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    N Engl J Med. 2002 Sep 26;347(13):975-82 PMID: 12324553
  24. Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease.
    Am J Gastroenterol. 2002 Nov;97(11):2861-70 PMID: 12425561
  25. Liver fibrosis -- from bench to bedside.
    J Hepatol. 2003;38 Suppl 1:S38-53 PMID: 12591185
  26. The C-X-C chemokine IP-10 stimulates HIV-1 replication.
    Virology. 2003 Mar 1;307(1):122-34 PMID: 12667820
  27. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.
    Clin Liver Dis. 2003 Feb;7(1):261-87 PMID: 12691470
  28. Expression of the chemokine IP-10 correlates with the accumulation of hepatic IFN-gamma and IL-18 mRNA in chronic hepatitis C but not in hepatitis B.
    J Med Virol. 2003 Aug;70(4):562-70 PMID: 12794718
  29. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C.
    Antiviral Res. 2003 Jun;59(1):1-11 PMID: 12834855
  30. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation.
    J Leukoc Biol. 2003 Sep;74(3):360-9 PMID: 12949239
  31. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies.
    J Antimicrob Chemother. 2004 Jan;53(1):15-8 PMID: 14645325
  32. Increased circulating and intrahepatic T-cell-specific chemokines in chronic hepatitis C: relationship with the type of virological response to peginterferon plus ribavirin combination therapy.
    Aliment Pharmacol Ther. 2004 Mar 1;19(5):551-62 PMID: 14987324
  33. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
    Ann Intern Med. 2004 Mar 2;140(5):346-55 PMID: 14996676
  34. Host factors and failure of interferon-alpha treatment in hepatitis C virus.
    Hepatology. 2004 Apr;39(4):880-90 PMID: 15057887
  35. Association of serum interleukin-8 with virologic response to antiviral therapy in patients with chronic hepatitis C.
    J Hepatol. 2004 May;40(5):845-52 PMID: 15094234
  36. Predictors of response to therapy for chronic hepatitis C.
    Semin Liver Dis. 2004;24 Suppl 2:25-31 PMID: 15346243
  37. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.
    Gastroenterology. 2000 Feb;118(2):346-55 PMID: 10648463
Article Info
Journal
Gut
Abbr.
Gut
ISSN
0017-5749
DOI
10.1136/gut.2005.074062
Published
2006-03-00
Epub
2005-00-08
Pages
374-9
Language
English
Region
England
NLM ID
2985108R
PMCID
PMC1856069
Subset
IM
External Links
PubMed source DOI: 10.1136/gut.2005.074062 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2